Adjuvant Alectinib Maintains Quality of Life During 2 Years of Treatment in Resected ALK-Positive NSCLC
Adjuvant alectinib was associated with early improvements in health-related quality of life that were maintained over 2 years of treatment in patients with resected ALK-positive non–small cell lung cancer (NSCLC). The new analysis of the phase III ALINA trial, reported by Dziadziuszko et al in The Lancet Oncology, also found a manageable safety profile with alectinib despite its substantially longer treatment duration compared with chemotherapy.
DAROL Examines Darolutamide With Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer
In a post hoc analysis of data from the fourth interim analysis of the DAROL trial, the androgen receptor darolutamide was well tolerated, with no cumulative toxic effects or new safety signals among patients with nonmetastatic castration-resistant prostate cancer receiving concomitant lipid-modifying agents. The results were published by Luz et al in a research letter in JAMA Network Open.
FDA Approves Topical Photodynamic Therapy for Superficial BCC
Today, the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for aminolevulinic acid hydrochloride topical gel, 10% (Ameluz), in combination with photodynamic therapy (PDT) using the BF-RhodoLED lamp series, for the treatment of superficial basal cell carcinoma (BCC) in adult patients.
New NCCN Survey Highlights Persistent Cancer Medication Shortages Across United States
The National Comprehensive Cancer Network® (NCCN®) has published updated data on the current impact of generic cancer medication shortages in the United States. The data come from survey responses from pharmacy directors and other clinical and administrative leadership at NCCN Member Institutions from late August of 2026.
SUO/AUA Updates Guidelines for Non–Muscle Invasive Bladder Cancer
The American Urologic Association (AUA), in partnership with the Society of Urologic Oncology (SUO) has released an amendment for 2026 to the Diagnosis and Treatment of Non–Muscle Invasive Bladder Cancer (NMIBC) Guideline, published in The Journal of Urology. The amendment introduces 40 new and updated recommendations regarding risk stratification, pathologic terminology, biomarkers, surveillance strategies, and treatment options.
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
From Results to Action: Leveraging Multidisciplinary Teams to Optimize NSCLC CareMore Top Stories
Surviving Cancer Put Me On a Career Path in Cancer Research
I was just 24 and in seemingly perfect health when I began experiencing unexplained abdominal pain so excruciating, even daily doses of pain medication failed to provide relief. I was a senior in college and had enrolled in a summer internship program at the University of California, Davis, when my ...
TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer
A lower-cost chemoimmunotherapy approach including triple oral metronomic chemotherapy (TMC) combined with ultra-low-dose immunotherapy termed TMC-I could extend survival for patients with advanced head and neck squamous cell carcinoma in resource-limited countries, according to investigators from...
‘Save Research’ Campaign Champions Federal Funding
ASCO members are leading the way to make sure Congress understands the critical importance of federal cancer research funding before the September 30 federal funding deadline. “The People Behind the Progress,” an ASCO social media series, features members sharing how federal cancer research has...
20th Annual Award for Leadership in Personalized Medicine
The Personalized Medicine Coalition (PMC), a nonprofit organization dedicated to advancing personalized medicine, recently announced that physician-scientist Norman E. “Ned” Sharpless, MD, has been selected as the recipient of the 20th Annual Award for Leadership in Personalized Medicine,...
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
On September 18, the U.S. Food and Drug Administration (FDA) approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio) for adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with...
Envafolimab Regimen Improves Pathologic Complete Response in MSS Locally Advanced Rectal Cancer
Adding the subcutaneous PD-L1 blocker envafolimab to short-course radiotherapy and CAPEOX (capecitabine and oxaliplatin) improved pathologic complete response (pCR) without a clear safety or surgical feasibility penalty in patients with microsatellite-stable (MSS) locally advanced rectal cancer,...
First-Line Amivantamab/Chemotherapy in EGFR Exon 20 Insertion–Positive Advanced NSCLC
Results from the phase III PAPILLON study show that first-line amivantamab plus carboplatin/pemetrexed (amivantamab/chemotherapy) was associated with numerically longer overall survival compared with chemotherapy in patients with previously untreated advanced non–small cell lung cancer (NSCLC)...
